Robotic Surgery Transforms Treatment of Urological Cancers

For decades, urologists faced a hard choice when treating cancers of the kidney, bladder, and penis: perform large, traumatic open surgeries that left patients in pain for weeks, or attempt delicate laparoscopic procedures through tiny ports that limited what surgeons could actually see and do. Robotic surgical platforms have begun to change that calculation entirely. As the technology becomes more widely available, more affordable, and more refined—incorporating advances like augmented reality to sharpen precision—it is reshaping how these cancers are managed, particularly in settings like India where access to cutting-edge surgical tools was once limited.

Dr. Himanshu Sharma, a uro-robotic surgeon at Ruby Hall Clinic in Pune, describes the shift as transformative. Robotic platforms, he explains, allow surgeons to perform complex procedures with greater precision while patients recover faster and spend less time in the hospital. The technology itself has come a long way since its introduction in 1994, evolving from a novelty into a practical tool that is now being deployed across the full spectrum of urological cancers.

Consider kidney cancer. Historically, the only option was radical nephrectomy—removing the entire kidney along with the tumor. Then came the realization that for smaller tumors, surgeons could preserve the healthy kidney tissue by removing only the affected portion, a technique called partial nephrectomy. But performing this delicate work through open surgery meant long incisions, significant blood loss, extended hospital stays, and considerable post-operative pain. Laparoscopic approaches reduced some of those burdens but introduced new ones: the instruments lacked the wrist-like flexibility surgeons needed, and stitching the kidney back together was technically grueling. Robotic systems solve both problems. The surgeon sits at a console with superior ergonomics, manipulating instruments that move with natural wrist motion. Dissection becomes smoother, suturing becomes feasible, and more patients can keep their kidneys. The payoff extends beyond the immediate recovery: preserving kidney function can eliminate the need for dialysis down the road, allowing people to live longer, healthier lives.

Bladder cancer presents a different challenge. About one in four patients with bladder cancer develop the muscle-invasive form, which requires removing the entire bladder and then reconstructing a new one to hold urine. This is among the most demanding procedures in urology. Traditionally performed through large open incisions, it carries substantial complication rates and leaves vulnerable patients facing long, painful recoveries. Robotic surgery allows surgeons to perform the entire procedure—removal and reconstruction—through keyhole incisions. The robot's precision makes it possible to build a new bladder entirely within the body using robotic techniques, something that is nearly impossible to accomplish laparoscopically. Patients achieve near-normal functional outcomes while avoiding the trauma of open surgery.

Penile cancer surgery has long been hampered by a particular problem: removing the lymph nodes in the groin, which is often necessary for complete cancer treatment. Open groin node surgery causes severe complications—wound infections, fluid accumulation, chronic pain—that can be as debilitating as the cancer itself. Surgeons have called this the Achilles heel of penile cancer treatment. A newer robotic technique called Video Endoscopic Inguinal Lymphadenectomy, or VEIL, performs the same operation through minimally invasive ports. The result is a dramatic reduction in wound complications and a far gentler experience for patients who already face a difficult diagnosis.

What makes this moment significant is not just the technology itself but its trajectory. Robotic systems are becoming cheaper, more available, and more refined. In a country like India, where healthcare resources are stretched thin and access to advanced surgery has been limited, this democratization of robotic capability could reshape treatment for thousands of patients. The machines are no longer confined to elite centers in wealthy nations. As costs continue to fall and surgeons gain experience, robotic-assisted urological cancer surgery is poised to become standard care rather than an exception—offering ordinary patients the kind of precision, recovery, and functional outcomes that were once available only to the few.